ArticleBlood2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.
Othman Al-Sawaf et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it
ArticleBlood2025
Othman Al-Sawaf et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.